Cipla

What Cipla does

Cipla Ltd. is an Indian multinational pharmaceutical company founded in 1935 and headquartered in Mumbai, operating as India's third-largest pharma firm by revenue with a Rs 28,163 crore (~$3.4B) top line in FY26. The company manufactures and commercializes a diversified portfolio spanning respiratory drugs (flagship brand Foracort crossing Rs 1,000 crore; approved and pipeline complex generics including gVentolin, gAdvair, gSymbicort), oncology products (Nintedanib holding ~50% US share, Lanreotide), chronic disease medications, and consumer healthcare through its Cipla Health subsidiary. Its technology base is anchored in vertically integrated respiratory API manufacturing (India, China, US), inhalation formulation expertise, and emerging capabilities in biosimilars (Kemwell JV), stem cell therapy (Ciplostem with Stempeutics), and CAR-T cell therapy (MedTherapy partnership reducing production timelines from weeks to one day at 70% lower cost).

The business model is anchored in generics manufacturing and branded prescription sales distributed through direct sales forces in India (One India Business contributing 45% of revenue), US generics distribution ($780M, targeting $1B run-rate by FY27), and channel partnerships across Africa (21% YoY growth) and other emerging markets. Regulatory approvals (285 ANDAs/NDAs in the US, US FDA VAI classification for the Goa facility, first AB-rated generic Ventolin from the Fall River plant) serve as primary value drivers, with new CEO Achin Gupta targeting 10% revenue from innovation-led products (biosimilars, complex generics, advanced therapies) within five years. Go-to-market is sales-led through physician detailing and enterprise healthcare relationships, supplemented by strategic distribution partnerships (Eli Lilly for Yurpeak, MannKind for inhaled insulin). The company employs over 22,000 people globally, maintains a net cash position of Rs 10,526 crore, and is publicly listed on Indian exchanges (NSE: CIPLA) with a market capitalization of approximately Rs 1.14 lakh crore.

Name

Cipla

Legal name

Cipla Ltd.

Website

https://cipla.com

Company type

Public

Founded year

1935

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cipla is an Indian multinational pharmaceutical company founded in 1935, manufacturing generic and specialty drugs across respiratory, oncology, and chronic disease categories, with operations in India, the US, and Africa serving healthcare providers, hospitals, and patients.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Chemical and Allied Products Merchant Wholesalers (4246)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Specialty Pharmaceutical Distributors (HLAIAJAB), Biologics & Biosimilars Distributors (HLAIAJAH), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Generic pharmaceuticals
• Respiratory medications
• Complex generics
• Biosimilars development
• Oncology drugs

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generics (India): India contributes nearly 45% of consolidated revenue with strong 15% YoY growth. One India Business surpassed ₹12,500 crore annual revenue milestone growing 15% YoY. Chronic therapies account for over 60% of branded prescription business. Domestic market growth of 14.2% driven by respiratory, diabetes, and cardiovascular segments.
2. North America Generics: US revenues declined 16% year-on-year to $780 million in FY26, driven by expected losses from generic Revlimid sales and manufacturing disruptions at partner Pharmathen halting Lanreotide output. Company targets FY27 exit run-rate of $1 billion through planned launches of four respiratory generics (gVentolin, gAdvair, gSymbicort approved/expected) plus three peptide/complex generics.
3. Africa and Emerging Markets: Africa business delivered strong 21% YoY growth in Q4 FY26 with 14% growth in dollar terms. The company maintains distribution partnerships and direct presence across African and emerging markets for generics and branded products.
4. Innovation Products: Innovation expected to contribute meaningful portion of revenues by Cipla's centenary in about 10 years. Currently ~10% revenue target in five years from innovation-led products including complex generics, biosimilars, stem cell and gene therapies.
5. Consumer Healthcare (Cipla Health): Cipla Health subsidiary, led by new CEO Shivam Puri transitioning to One India Business leadership, manages consumer healthcare and wellness portfolio including smoking cessation, pain care, cough and cold, skincare, haircare, and nutrition products.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Cipla manufactures and distributes a broad portfolio of generic and specialty pharmaceutical products spanning respiratory, oncology, anti-diabetic, cardiovascular, and chronic disease therapies. The company sells branded generics in India through its One India Business, complex generics and inhalation products in the United States via FDA-approved facilities, and essential medicines across Africa and emerging markets, while building an innovation pipeline in biosimilars, stem cell therapy (Ciplostem), and CAR-T cell therapy.

Product overview

Cipla is a pharmaceutical company offering a diversified portfolio of branded generic drugs and specialty medicines across multiple therapy areas. The core offerings include respiratory products (Foracort, gVentolin, gFlovent, gAdvair, gSymbicort), oncology drugs (Nintedanib, Lanreotide), and novel therapies (Ciplostem stem cell therapy, CAR-T cell therapy through partnership with MedTherapy). The company operates through its One India business unit contributing nearly 45% of consolidated revenue, with additional portfolios in consumer healthcare via Cipla Health subsidiary. Strategic focus areas include complex generics, biosimilars (JV with Kemwell Biopharma), and differentiated respiratory products, with generics remaining the mainstay at over 80% of business.

Differentiator

Problem solved

Functional benefit

Brands

• Foracort: Flagship respiratory brand that crossed Rs 1,000 crore revenue milestone during FY26
• Ifosfamide
• Ciplostem
• Yurpeak
• MannKind Partnership

Products and services

• Foracort

Quantifiable outcome

• Foracort flagship respiratory brand crossed ₹1,000 crore revenue milestone during FY26
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• StempeuticscoreStrategic or Co-development Partner · 2 June 2026Partnership with Stempeutics to launch Ciplostem, a stem-cell therapy for Grade II-III knee osteoarthritis approved by DCGI. Single-dose intra-articular treatment targeting India's 48 million osteoarthritis patients to slow disease progression and improve joint function.
• MedTherapy BiotechcoreStrategic or Co-development Partner · 27 May 2026Tata Sons-backed biotech startup partnered with Cipla for commercialization of CAR-T cell therapy for blood cancer in India. Cipla handles branding and distribution once regulatory approvals are secured. MedTherapy's manufacturing platform reduces CAR-T production from several weeks to one day with 70% cost reduction. Facility planned in Uttar Pradesh targeting 50,000-100,000 patients annually. Therapy currently in Phase II clinical trials in India.
• Eli LillyminorChannel Partner/ Reseller/ DistributorPartnership with Eli Lilly for distribution of Yurpeak (tirzepatide/GLP-1 drug) in India, expanding Cipla's presence in the rapidly growing anti-diabetic and obesity treatment market.
• Kemwell BiopharmacoreStrategic or Co-development PartnerJoint venture with Kemwell Biopharma for focused biosimilars pipeline aligned with Cipla's core therapeutic strengths. Plans to add 1-2 products every year over the next 5-6 years targeting the fast-growing biosimilars market for biologic drugs.
• Fennec PharmaceuticalsminorOEM/ Whitelabel/ Licensing PartnerLicensing agreement extension with Fennec Pharmaceuticals for PEDMARK (sodium thiosulfate), extending market exclusivity to at least September 1, 2033. Settlement agreement securing continued market access for pediatric cisplatin-induced hearing loss protection.
• Inzpera HealthsciencesminorStrategic or Co-development PartnerCompleted acquisition of Inzpera Healthsciences for Rs 110.65 crore, expanding specialty products portfolio.

Scale indicators13 records

Recent moves7 records

Expansion highlights8 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a comparable diversified generics and specialty portfolio spanning respiratory, chronic disease and complex generics across India, US and emerging markets. Direct competitor in respiratory franchise and US generics.
• Dr. Reddy's Laboratories: Major Indian pharma with parallel exposure to US generics (large ANDA portfolio), complex generics, biosimilars and emerging markets. Direct head-to-head competitor for US generic launches including respiratory.
• Lupin Limited: Indian pharma with strong respiratory franchise (Lupin's Spiriva and generic Advair programs) and US generics presence — directly comparable to Cipla's respiratory differentiation strategy and complex generic pipeline.
• Aurobindo Pharma: Indian pharma heavily exposed to US generics with large ANDAs and injectables portfolio. Competes directly with Cipla in US generic launches, oral solids and emerging market branded generics.
• Zydus Lifesciences (Cadila Healthcare): Indian pharma with biosimilars leadership (similar to Cipla-Kemwell JV), complex generics and US presence. Direct peer in biosimilars ambition and chronic disease domestic franchise.
• Glenmark Pharmaceuticals: Indian pharma with specialty/OTC focus across emerging markets and complex generics in US. Comparable geographic mix and respiratory/allergy portfolio overlap.
• Torrent Pharmaceuticals: Indian pharma with chronic disease focus (cardio, diabetes, CNS) and growing emerging markets presence. Comparable domestic chronic therapy franchise and respiratory/generics strategy.
• Biocon Limited: Indian biopharma with leading biosimilars portfolio and emerging markets focus. Comparable innovation ambition, biosimilars pipeline and partnership-led global commercialization model.

Broad incumbents

• Teva Pharmaceutical Industries: Global generics leader with broad respiratory franchise and large US generics footprint. Overlaps with Cipla in respiratory generics (Advair, Symbicort, ProAir) and complex injectables but operates at much greater global scale.
• Viatris: Global generics and specialty pharma with extensive US distribution and biosimilars pipeline. Direct competitor for US generic launches and biosimilars commercialization overlap.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ciplacsi2014
• Facebookfacebook.com/207716982590230
• LinkedInlinkedin.com/company/37173

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cipla